Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.

Papavasileiou, Evangelia

Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration. [electronic resource] - Retina (Philadelphia, Pa.) Apr 2013 - 846-53 p. digital

Publication Type: Journal Article

1539-2864

10.1097/IAE.0b013e318271f278 doi


Aged
Aged, 80 and over
Angiogenesis Inhibitors--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Choroid Diseases--drug therapy
Combined Modality Therapy
Endotamponade
Female
Fibrinolytic Agents--therapeutic use
Fluorocarbons--administration & dosage
Humans
Intravitreal Injections
Male
Middle Aged
Photochemotherapy
Polyps--drug therapy
Prone Position
Ranibizumab
Retinal Hemorrhage--drug therapy
Retrospective Studies
Tissue Plasminogen Activator--therapeutic use
Tomography, Optical Coherence
Visual Acuity--physiology
Wet Macular Degeneration--complications